Phoenix Biotech Acquisition a Aktie
WKN DE: A3DE3Y / ISIN: US71902K1051
05.09.2025 18:07:39
|
CERo Therapeutics Stock Drops 13% Despite FDA Fast Track For Lead AML Therapy
(RTTNews) - CERo Therapeutics Holdings, Inc. (CERO) fell 12.77 percent to $6.05 on Friday, down $0.88, after announcing that the U.S. Food and Drug Administration granted Fast Track Designation to its lead investigational compound, CER-1236, for Acute Myeloid Leukemia. The stock opened at $6.40 and traded between $5.41 and $6.70, compared to a previous close of $6.93 on the New York Stock Exchange. Trading volume surged to 4.3 million shares, well above the average of 1.1 million. Shares now sit at the bottom of their 52-week range of $5.41 to $896.00, highlighting ongoing volatility despite the regulatory milestone.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Phoenix Biotech Acquisition Corp Registered Shs -A-mehr Nachrichten
Keine Nachrichten verfügbar. |